PL3669892T3 - Kompozycja do zastosowania w metodzie immunostymulacyjnej - Google Patents

Kompozycja do zastosowania w metodzie immunostymulacyjnej

Info

Publication number
PL3669892T3
PL3669892T3 PL20155567.9T PL20155567T PL3669892T3 PL 3669892 T3 PL3669892 T3 PL 3669892T3 PL 20155567 T PL20155567 T PL 20155567T PL 3669892 T3 PL3669892 T3 PL 3669892T3
Authority
PL
Poland
Prior art keywords
composition
immunostimulatory method
immunostimulatory
Prior art date
Application number
PL20155567.9T
Other languages
English (en)
Inventor
David Charles Jackson
Amabel Tan
Weiguang Zeng
Original Assignee
Ena Respiratory Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010904284A external-priority patent/AU2010904284A0/en
Application filed by Ena Respiratory Pty Ltd filed Critical Ena Respiratory Pty Ltd
Publication of PL3669892T3 publication Critical patent/PL3669892T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20155567.9T 2010-09-22 2011-09-22 Kompozycja do zastosowania w metodzie immunostymulacyjnej PL3669892T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010904284A AU2010904284A0 (en) 2010-09-22 Novel Immunostimulatory Method
AU2011902408A AU2011902408A0 (en) 2011-06-20 Novel immunstimulatory method

Publications (1)

Publication Number Publication Date
PL3669892T3 true PL3669892T3 (pl) 2024-10-07

Family

ID=45873313

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11826223T PL2618842T3 (pl) 2010-09-22 2011-09-22 Nowa metoda immunostymulacyjna
PL20155567.9T PL3669892T3 (pl) 2010-09-22 2011-09-22 Kompozycja do zastosowania w metodzie immunostymulacyjnej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11826223T PL2618842T3 (pl) 2010-09-22 2011-09-22 Nowa metoda immunostymulacyjna

Country Status (10)

Country Link
US (5) US9676819B2 (pl)
EP (3) EP3520814A1 (pl)
JP (6) JP2013537892A (pl)
CN (2) CN103189072B (pl)
AU (1) AU2011305061B2 (pl)
CA (1) CA2811957C (pl)
DK (1) DK2618842T3 (pl)
ES (2) ES2735274T3 (pl)
PL (2) PL2618842T3 (pl)
WO (1) WO2012037612A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
US20170274068A1 (en) * 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent
RU2017126206A (ru) 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
US11464853B2 (en) 2016-02-26 2022-10-11 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN118161614A (zh) * 2017-03-31 2024-06-11 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
US20210177795A1 (en) * 2017-12-21 2021-06-17 Ena Therapeutics Pty Ltd Administering compounds
CN111491943A (zh) 2017-12-21 2020-08-04 艾娜医疗私人有限公司 优化的化合物
WO2020257870A1 (en) 2019-06-26 2020-12-30 Ena Therapeutics Pty Ltd Novel molecules
US20230043518A1 (en) * 2019-09-04 2023-02-09 Axelia Oncology Pty Ltd Cancer immunotherapy
AU2020343725A1 (en) * 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer treatment

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
CA2391843C (en) 1999-11-19 2011-10-18 Csl Limited Hcv vaccine compositions
ES2305086T3 (es) * 2000-05-19 2008-11-01 Corixa Corporation Tratamiento profilactico y terapeutico de enfermedades alergicas, autoinmunes e infecciosas con compuestos con base de monosacaridos.
EP1382352A1 (de) * 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
EP2301972A1 (en) * 2002-08-12 2011-03-30 The Council Of The Queensland Institute Of Medical Research Method to prepare immunogenic lipopeptides comprising T-helper and B-cell epitopes
BR0313101A (pt) 2002-08-12 2005-06-28 Queensland Inst Med Res Novos lipopeptìdeos imunogênicos que compreendem epitopos de linfócitos t-helper e linfócitos t citotóxicos (ctl), e métodos para sua produção e uso
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
CN1921877A (zh) * 2004-01-16 2007-02-28 悉生物有限公司 陪伴蛋白10对Toll样受体诱导的细胞因子和趋化因子分泌的调节
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
CA2584562A1 (en) 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
MX2007007586A (es) 2004-12-21 2007-12-10 Vaxinnate Corp Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.
CA2597008A1 (en) 2005-02-08 2006-08-17 The Council Of The Queensland Institute Of Medical Research Immunogenic molecules
EP1858326A4 (en) 2005-02-22 2008-10-15 Univ California METHOD FOR THE TREATMENT OF STOMACH-DARM-INFLAMMATION
WO2008085549A2 (en) 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
JP5743315B2 (ja) * 2007-10-09 2015-07-01 ザ ユニバーシティー オブ メルボルン トランスフェクション方法及びそのための組成物
WO2009137103A2 (en) 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
US8728465B2 (en) 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
US20110171259A1 (en) 2008-09-05 2011-07-14 Martin Gagne Novel Compositions and Adjuvants
EP2396328A2 (en) * 2009-02-11 2011-12-21 The Regents of The University of California Toll-like receptor modulators and treatment of diseases
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
EP2338521A1 (en) 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
KR101853513B1 (ko) 2010-03-23 2018-04-30 노파르티스 아게 감염, 염증, 호흡기 질환 등의 치료를 위해 사용되는 ｔｌｒ2 효능제로서의 화합물 (시스테인 기재 리포펩티드) 및 조성물
CA2811957C (en) * 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
US20170274068A1 (en) 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent

Also Published As

Publication number Publication date
CN105477640B (zh) 2019-09-17
CN105477640A (zh) 2016-04-13
WO2012037612A1 (en) 2012-03-29
CN103189072B (zh) 2018-02-09
JP2025143357A (ja) 2025-10-01
JP2013537892A (ja) 2013-10-07
JP2019167369A (ja) 2019-10-03
US20130230544A1 (en) 2013-09-05
US10406100B2 (en) 2019-09-10
CA2811957A1 (en) 2012-03-29
US20220296505A1 (en) 2022-09-22
EP3669892A1 (en) 2020-06-24
EP3669892C0 (en) 2024-05-08
US11786458B2 (en) 2023-10-17
US20170246312A1 (en) 2017-08-31
EP2618842B1 (en) 2019-04-24
JP7497962B2 (ja) 2024-06-11
US20240050364A1 (en) 2024-02-15
PL2618842T3 (pl) 2019-10-31
AU2011305061A1 (en) 2013-05-02
AU2011305061B2 (en) 2016-04-14
US11351114B2 (en) 2022-06-07
ES2735274T3 (es) 2019-12-17
DK2618842T3 (da) 2019-07-01
US20190380952A1 (en) 2019-12-19
EP2618842A4 (en) 2014-03-26
EP3669892B1 (en) 2024-05-08
JP6657507B2 (ja) 2020-03-04
EP3520814A1 (en) 2019-08-07
CN103189072A (zh) 2013-07-03
ES2980738T3 (es) 2024-10-02
CA2811957C (en) 2019-04-16
JP2021130713A (ja) 2021-09-09
JP2017061504A (ja) 2017-03-30
EP2618842A1 (en) 2013-07-31
JP2023113902A (ja) 2023-08-16
US9676819B2 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
PL3669892T3 (pl) Kompozycja do zastosowania w metodzie immunostymulacyjnej
GB201016001D0 (en) Composition and method
GB201001833D0 (en) Method
GB201007353D0 (en) Method
GB201007354D0 (en) Method
GB201011513D0 (en) Method
GB201004759D0 (en) Method
GB201003531D0 (en) Composition and method
EP2601936A4 (en) COMPRESSED COMPOSITION
GB201006306D0 (en) Method
GB201012148D0 (en) Method
GB201008364D0 (en) Composition and method
GB201012784D0 (en) Method
GB201010855D0 (en) Method
GB201008843D0 (en) Method and composition
GB201007207D0 (en) Method
PL119426U1 (pl) Ławka
IL223436A (en) Methods for preparing tetranor - pgdm and tetranor - pgjm
GB201017003D0 (en) Method
GB201007522D0 (en) Method
IL225307A0 (en) A method for the preparation of rumi urine
GB201004097D0 (en) Improvements in packaging
PH32009000131S1 (en) Bench
GB201004760D0 (en) Method
GB201021435D0 (en) Method